Scientists map cell types in oral cancer to unlock early detection
NCT ID NCT07579507
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to understand the different cell types in oral cancer and pre-cancerous mouth lesions. Researchers will analyze tissue and blood samples from 150 participants to map gene activity and cell interactions. They will also test whether a simple brush sample can replace traditional biopsies for diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better understanding of how oral cancer develops and potentially improve early detection methods.
- What could go wrong
- This is an observational study, not a treatment trial. It is still in early stages and may not directly lead to new diagnostics or therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * I1: Male or female at least 18 years old. * I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD. * I3: Patient who has agreed to participate in this research and sign consent. * I4: Patient affiliated to a medical insurance. * I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy) Exclusion Criteria: * NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment. * NI2: Pregnant or nursing woman. * NI3: Contraindication to general anesthesia. * NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...). * NI5: Patient under curatorial or guardianship or placed under the protection of justice.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Oral potentially malignant disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Léon Bérard
Lyon, 69008, France